Project Grant H8G48288

The National Science Foundation (NSF) awarded a $997,689 Cooperative Agreement under its NSF Technology, Innovation, and Partnerships (CFDA 47.084) program to Omnicyte LLC, a minority-owned small business in Branford, CT. The funding supports the design and production of a next-generation COVID-19 vaccine that addresses weaknesses of current vaccines, such as reduced booster effectiveness, short-lived efficacy, and side effects. The project aims to develop a vaccine candidate with improved...

Federal Cooperative Agreement Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded Boston Children's Hospital a Cooperative Agreement valued at $1.67 million under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct a Phase 1 clinical study of a novel messenger ribonucleic acid (mRNA)-based severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine. The research, initiated September 25, 2025, and scheduled for completion by July...

Federal Cooperative Agreement Summary The National Center for Immunization and Respiratory Diseases awarded a $850,000 Cooperative Agreement to the University of Colorado-Denver on September 1, 2025, under the CDC Investigations and Technical Assistance program (CFDA 93.283). The award, titled "Rapid-Cycle Survey Collaborative for Public and Provider Input on Immunization Issues: Vaccine Policy Collaborative Initiative" (IP25-111), supports a five-year project period through August 31,...

Invvax, Inc. received a $996,606 Cooperative Agreement from the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) effective July 1, 2025, through June 30, 2027. The award supports a Small Business Innovation Research (SBIR) Phase II project focused on developing Stable Prophylactic Antibodies (SPABs) that maintain efficacy over extended periods. The primary deliverable is the creation of enhanced antibody mutations that significantly...

Viva Viral Vaccines, Inc. received a $299,968 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective September 25, 2025, through August 31, 2026. The project is being conducted in Ithaca, New York. The award funds development of a broad-spectrum, multivalent vaccine platform targeting influenza neuraminidase (NA) protein that addresses critical limitations in current...

Federal Project Grant Award Summary Massachusetts General Hospital received a $676,666 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) effective September 3, 2025, with a completion date of August 31, 2030. The award funds research into spatial and temporal adjuvant delivery mechanisms designed to enhance messenger RNA (mRNA) vaccine efficacy and durability. The project will...

This federal Project Grant award of $360,000 from the National Science Foundation's (NSF) Division of Mathematical Sciences and the CDC Coronavirus and Other Respiratory Viruses Division aims to improve policymaking processes for mitigating the transmission of respiratory pathogens, such as during the COVID-19 pandemic. The principal investigators will develop and study game theoretical mathematical models, simulation tools, and numerical approaches that can be adapted to specific public...

Federal Cooperative Agreement Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded a Cooperative Agreement totaling $1,554,990 to the University of Maryland, Baltimore on September 20, 2025, under the Allergy and Infectious Diseases Research program (CFDA 93.855). This research initiative aims to identify the molecular determinants governing durable versus transient antibody responses following vaccination. The primary deliverable consists of a prospective clinical...

Federal Project Grant Award Summary Brigham & Women's Hospital Inc., Department of Faulkner Pathology, received a $194,400 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective September 15, 2025, with completion targeted for August 31, 2029. The award supports research examining vaccine immunogenicity and adoptive transfer of immunity in allogeneic hematopoietic stem cell...

Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded $223,728 to The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. on May 22, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop and evaluate a whole inactivated vaccine against Enterovirus D68 (EV-D68). This Project Grant will support research through April 30, 2028, addressing a significant public health gap, as EV-D68 is a...